Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma

P. Vockova, M. Svaton, J. Karolova, E. Pokorna, M. Vokurka, P. Klener

. 2020 ; 66 (1) : 17-23.

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21014125

Diffuse large B-cell lymphoma (DLBCL) is the most common and one of the most aggressive subtypes of non-Hodgkin's lymphomas. Front-line therapy consists of chemotherapy in combination with anti-CD20 monoclonal antibody rituximab. Relapses after rituximab-based regimen have poor prognosis and call for new treatment options. Immunohistochemistry analysis of relapsed DLBCL often reveal CD20-negative lymphoma, which limits repeated use of rituximab in combination with salvage chemotherapy. CD38 is a surface antigen that binds to CD38, CD31/PECAM-1 and hyaluronic acid. CD38 is an important mediator of signal transmission from the microenvironment into the cell. Anti-CD38 monoclonal antibody daratumumab has been approved for the treatment of multiple myeloma. Expression of CD38 on the surface of DLBCL is highly variable (compared to strong expression on myeloma cells), but can be easily assessed by flow cytometry or immunohistochemistry. A patient-derived xenograft (PDX) model of CD20-negative, CD38-positive DLBCL derived from a patient with rituximab-refractory DLBCL was used for in vivo experiments. We demonstrated that daratumumab suppressed growth of subcutaneous PDX tumours significantly more effectively than rituximab. Analysis of tumours obtained from mice treated with daratumumab revealed down-regulation of surface CD38, suggesting endocytosis of CD38-daratumumab complexes. The results suggest a potential clinical use of daratumumab in combination with salvage chemotherapy in patients with relapses of CD20-negative DLBCL. In addition, daratumumab might potentially serve as a suitable antibody moiety for derivation of antibodydrug conjugates for the targeted delivery of toxic payloads to the lymphoma cells.

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc21014125
003      
CZ-PrNML
005      
20220725124654.0
007      
ta
008      
210504s2020 xr d f 000 0|eng||
009      
AR
035    __
$a (PubMed)32512655
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Vočková, Petra $7 xx026016501 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; 1st Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
245    10
$a Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma / $c P. Vockova, M. Svaton, J. Karolova, E. Pokorna, M. Vokurka, P. Klener
504    __
$a Literatura
520    9_
$a Diffuse large B-cell lymphoma (DLBCL) is the most common and one of the most aggressive subtypes of non-Hodgkin's lymphomas. Front-line therapy consists of chemotherapy in combination with anti-CD20 monoclonal antibody rituximab. Relapses after rituximab-based regimen have poor prognosis and call for new treatment options. Immunohistochemistry analysis of relapsed DLBCL often reveal CD20-negative lymphoma, which limits repeated use of rituximab in combination with salvage chemotherapy. CD38 is a surface antigen that binds to CD38, CD31/PECAM-1 and hyaluronic acid. CD38 is an important mediator of signal transmission from the microenvironment into the cell. Anti-CD38 monoclonal antibody daratumumab has been approved for the treatment of multiple myeloma. Expression of CD38 on the surface of DLBCL is highly variable (compared to strong expression on myeloma cells), but can be easily assessed by flow cytometry or immunohistochemistry. A patient-derived xenograft (PDX) model of CD20-negative, CD38-positive DLBCL derived from a patient with rituximab-refractory DLBCL was used for in vivo experiments. We demonstrated that daratumumab suppressed growth of subcutaneous PDX tumours significantly more effectively than rituximab. Analysis of tumours obtained from mice treated with daratumumab revealed down-regulation of surface CD38, suggesting endocytosis of CD38-daratumumab complexes. The results suggest a potential clinical use of daratumumab in combination with salvage chemotherapy in patients with relapses of CD20-negative DLBCL. In addition, daratumumab might potentially serve as a suitable antibody moiety for derivation of antibodydrug conjugates for the targeted delivery of toxic payloads to the lymphoma cells.
650    _2
$a antigeny CD38 $x antagonisté a inhibitory $7 D051997
650    _2
$a zvířata $7 D000818
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $7 D000971
650    _2
$a lidé $7 D006801
650    12
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $7 D016403
650    _2
$a membránové glykoproteiny $x antagonisté a inhibitory $7 D008562
650    _2
$a myši $7 D051379
650    _2
$a rituximab $x terapeutické užití $7 D000069283
650    _2
$a nádorové mikroprostředí $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Svatoň, Michael $7 xx0238165 $u CLIP - Laboratory Centre Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Karolová, Jana. $7 xx026016401 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; 1st Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
700    1_
$a Pokorná, Eva $7 xx0063982 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Vokurka, Martin, $d 1962- $7 jn20001005320 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Klener, Pavel, $d 1975- $7 xx0105452 $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic; 1st Department of Medicine - Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 66, č. 1 (2020), s. 17-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32512655 $y Pubmed
856    41
$u https://fb.cuni.cz/file/5917/fb2020a0003.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20210504 $b ABA008
991    __
$a 20220725124652 $b ABA008
999    __
$a ok $b bmc $g 1657538 $s 1134513
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 66 $c 1 $d 17-23 $i 0015-5500 $m Folia biologica (Praha) $n Folia biol. (Praha) $x MED00011004
LZP    __
$b NLK118 $a Pubmed-20210504

Find record

Citation metrics

Archiving options